Prior Authorization Request Form for Selarsdi/Imuldosa/Yesintek IV (ustekinumab products)
This document is a Cigna prior authorization request form to be completed by prescribers for infusion/medical benefit administration or pharmacy dispensing of Selarsdi, Imuldosa, or Yesintek 130mg/26mL (ustekinumab IV) products. It collects patient, prescriber, medication, indication, administration site, and clinical information to support coverage review.
No material clinical/coverage changes — this document is an administrative prior authorization form used to collect information for coverage review.
Policy overview
This is a Cigna prior authorization request form to be completed by prescribers for infusion/medical benefit administration or pharmacy dispensing of Selarsdi, Imuldosa, or Yesintek 130mg/26mL (ustekinumab IV). The form collects administrative and clinical data to support coverage review, including patient and prescriber identification (required asterisked fields such as patient name, Cigna ID, date of birth, physician name, DEA/NPI/TIN), medication requested and dosing details (product selection, dose/quantity, frequency, duration, J‑code, ICD‑10, patient weight), the indication/diagnosis (e.g., ankylosing spondylitis, Crohn’s disease, plaque psoriasis, psoriatic arthritis, ulcerative colitis, other), and clinical information (use with other biologic or targeted synthetic agents and disease‑specific items such as induction therapy and gastroenterology prescriber status for Crohn’s/ulcerative colitis).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.